



Syngene International Limited

Ref: Syn/CS/SE/PR/2020-21/July/40

Biocon SEZ, Biocon Park, Plot No. 2 &
3, Bommasandra Industrial Area, IV
Phase, Jigani Link Road, Bengaluru
560 099, Karnataka, India

T +91 80 6891 8000

F +91 80 6891 8808

CIN: L85110KA1993PLC01493

www.syngeneintl.com

July 21, 2020

To, The Manager Listing BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager Listing National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Dear Sir/Madam,

Sub: Press Release in respect of results for the quarter ended June 30, 2020

With reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, please find enclosed the press release titled **“Syngene announces Q1 FY21 results - Revenue Rs. 437 Cr; EBITDA Rs. 140 Cr; PAT Rs. 58 Cr; CRISIL long term rating upgraded to AA+ from AA.”**

The above-mentioned press release will also be available on website of the Company www.syngeneintl.com.

This is for your information and records.

Thanking You,

Yours faithfully,

For **SYNGENE INTERNATIONAL LIMITED**

Priyadarshini Mahapatra

Company Secretary & Compliance Officer

E: priyadarshini.mahapatra@syngeneintl.com

Enclosed: Press Release along with fact sheet

Syngene announces Q1 FY21 results

- Revenue Rs. 437 Cr; EBITDA Rs. 140 Cr; PAT Rs. 58 Cr
- CRISIL long term rating upgraded to AA+ from AA

Bengaluru, July 21, 2020:

Syngene International Limited today announced its Q1 FY21 results. The Company posted quarterly revenue of Rs. 437 Cr, in line with guidance: Profit After Tax, was impacted less than expected, at Rs. 58 Cr for the quarter.

Commenting on the results, **Mr. Jonathan Hunt, Managing Director and Chief Executive Officer - Syngene International Limited**, said: *“In line with our guidance, Q1 revenue was flat at Rs. 437 Cr compared to the same quarter last year due to the temporary suspension of operations during the nationwide lockdown. However, the implementation of protective measures allowed all divisions to restart gradually and operate at close to normal levels for the last six weeks of the quarter. Across the Company, our teams have worked hard to get projects back on schedule.*

Recent good news was the improved credit rating from CRISIL to AA+ with a stable outlook. This is welcome recognition from the rating agency of the Company’s business model, strong client relationships, robust processes and sound risk profile.

Overall Q1 performance was as expected and we look forward to returning to growth in 2Q.”

Quarterly Financial Highlights (All numbers in INR Cr except Margins)

	Q1 FY21	Q1 FY20	YoY Change (%)
Revenue	437	441	-1
Revenue from operations	422	421	0.2
EBITDA	140	142	-1
EBITDA Margin (%)	32	32	
PAT	58	72	-19
PAT Margin (%)	13	16	

Business Update

Syngene's first quarter performance was driven by solid performances in Discovery Services and the Dedicated Centres. The national lockdown resulted in a temporary suspension of operations in all divisions. Since restarting, the expansion of shift working and other protection measures for employees allowed the divisions to return to near normal levels of operation and get client projects largely back on schedule.

During the quarter, credit rating agency, CRISIL, conducted its annual review and based on its assessment of the Company's strong fundamentals, sound business model and robust liquidity position, upgraded Syngene's rating to AA+ /Stable from AA/Positive. The upgrade reflects sustained improvement in operating performance, driven by healthy revenue growth and operating profitability. Other factors include: Syngene's well-established market position in contract research; strong client base; and healthy financial risk profile.

As the COVID-19 pandemic continues to escalate, Syngene is actively engaged in various COVID-19 research and diagnostic projects. Its RT-PCR testing facility is supporting hospitals across Bangalore and has conducted more than 30,000 COVID-19 tests free of charge. It has also indigenously developed an ELISA testing kit that has been outsourced



Syngene

Putting Science to Work

EARNINGS RELEASE

Q1 FY 2020-21

to HiMedia for manufacturing and distribution across the country. In Development Services, Syngene is supplying reagents for use in diagnostic kits for COVID-19 testing and has signed a voluntary licensing agreement with Gilead for manufacturing and supply of Remdesivir in India and other markets.

Earnings Call

The Company will conduct a 60-minute call at 2.30 pm IST on 22nd July 2020 where the senior management will discuss the Company's performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time. The dial-in number for this call is +91 22 6280 1279 / +91 22 7115 8180. Other toll numbers are listed in the conference call invitation which is posted on the Company website www.syngeneintl.com. The operator will provide instructions on asking questions before the start of the call. A replay of this call will also be available till 1st August, 2020 on +91 22 7194 5757 / +91 22 6663 5757, Playback ID: 40395. We will aim to post the transcript of the conference call on the Company website within seven working days of the investor conference call.

About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022), is an integrated research, development and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors. Syngene's 4200 scientists offer both skills and the capacity to deliver great science, robust data management and IP security and quality manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, Bristol-Myers Squibb and Herbalife, as well as 1.9 Mn sq ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading edge science as well as multinationals including GSK and Merck KGaA. For more details, visit www.syngeneintl.com.

Contact details

Investor Contact	Media Contact
-------------------------	----------------------

Syngene

Putting Science to Work

Confidentiality

Quality

Innovation

Science



EARNINGS RELEASE

Q1 FY 2020-21

Krishnan G

P: +91 80 6891 9807

M: +919819992927

Fax: +91 80 2852 3423

E: Krishnan.G@syngeneintl.com

Sandeep Nair

P: +91 80 6891 8775

M: +91 88843 67776

Fax: +91 80 2852 3423

E: sandeep.nair@syngeneintl.com

Disclaimer: Certain of the statements that may be made or discussed at the conference call may be forward-looking statements and/or based on management's current expectations and beliefs concerning future developments and their potential effects upon Syngene International Limited ("Syngene") and its associates. There can be no assurance that future developments affecting Syngene and its associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties and there are important factors that could cause actual results to differ, possibly materially, from expectations reflected in such forward-looking statements. Syngene does not intend, and is under no obligation, to update any forward-looking statement made at the conference call.

SYNGENE GROUP

FACT SHEET

June - 2020

SYNGENE INTERNATIONAL LIMITED (CONSOLIDATED)		(Rs. Crores)	
BALANCE SHEET		30 June 2020	31 March 2020
ASSETS			
Non-current assets			
Property, plant and equipment	1,912	1,877	
Capital work-in-progress	210	234	
Right-of-use assets	84	86	
Investment property	41	36	
Intangible assets	18	21	
Financial assets			
(i) Investments	10	38	
(ii) Derivative assets	26	25	
(iii) Other financial assets	16	15	
Deferred tax assets (net)	116	123	
Income tax assets (net)	76	76	
Other non-current assets	16	19	
Total non-current assets	2,525	2,550	
Current assets			
Inventories	52	25	
Financial assets			
(i) Investments	781	738	
(ii) Trade receivables	281	398	
(iii) Cash and cash equivalents	342	193	
(iv) Bank Balances other than (iii) above	75	89	
(v) Derivative assets	16	19	
(vi) Other financial assets	80	69	
Other current assets	84	82	
Total current assets	1,711	1,613	
Total assets	4,236	4,163	
EQUITY AND LIABILITIES			
Equity			
Equity share capital	400	400	
Other equity	1,872	1,776	
Total equity	2,272	2,176	
LIABILITIES			
Non - current liabilities			
Financial liabilities			
(i) Lease liabilities	80	81	
(ii) Derivative liabilities	108	138	
Provisions	42	41	
Other non-current liabilities	188	188	
Total non-current liabilities	418	448	
Current liabilities			
Financial liabilities			
(i) Borrowings	425	309	
(ii) Lease liabilities	7	6	
(iii) Trade payables	233	222	
(iv) Derivative liabilities	40	55	
(v) Other financial liabilities	474	495	
Provisions	42	42	
Income tax liabilities (net)	12	11	
Other current liabilities	313	399	
Total current liabilities	1,546	1,539	
Total equity and liabilities	4,236	4,163	

SYNGENE INTERNATIONAL LIMITED (CONSOLIDATED)
PROFIT AND LOSS STATEMENT
(Rs. Crores, except per share data)

Particulars	Q1 FY 21	Q1 FY 20	Variance
<u>INCOME</u>			
Revenue from operations	422	421	0.2%
Other income	15	20	-25%
Total Revenue	437	441	-1%
<u>EXPENDITURE</u>			
Material and power costs	102	117	-13%
Staff costs	140	132	6%
Foreign exchange (net)	3	(2)	-306%
Other expenses	52	52	-1%
Material, power, staff, forex and other expenses	297	299	
EBITDA	140	142	-1%
Finance costs	8	7	4%
Depreciation and amortisation expenses	66	48	39%
PROFIT BEFORE TAX	66	87	-24%
Tax on above	8	15	
PROFIT AFTER TAX	58	72	-19%
EPS - Basic (not annualised)	1.47	1.82	
EPS - Diluted (not annualised)	1.46	1.81	

Note: a) The figures are rounded off to the nearest crore, percentages are based on absolute numbers:

SYNGENE INTERNATIONAL LIMITED (CONSOLIDATED)
PROFIT AND LOSS STATEMENT

(Rs. Crores, except per share data)

Particulars	Q1 FY 21	Q4 FY 20	Variance
<u>INCOME</u>			
Revenue from operations	422	607	-31%
Other income	15	21	-25%
Total Revenue	437	628	-30%
<u>EXPENDITURE</u>			
Material and power costs	102	156	-35%
Staff costs	140	164	-14%
Foreign exchange (net)	3	1	450%
Other expenses	52	82	-37%
Material, power, staff, forex and other expenses	297	403	
EBITDA	140	225	-38%
Finance costs	8	10	-20%
Depreciation and amortisation expenses	66	62	6%
PROFIT BEFORE TAX	66	153	-57%
Tax on above	8	33	
PROFIT AFTER TAX	58	120	-52%
EPS - Basic (not annualised)	1.47	3.03	
EPS - Diluted (not annualised)	1.46	3.02	

Note: a) The figures are rounded off to the nearest crore, percentages are based on absolute numbers